Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853242 · ClinicalTrials.gov registry record · Phase 2
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 349
- Enrollment target
NCT00853242 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 349 participants.
The verdict
NCT00853242, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 349 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.
Interventions
- DRUG Placebo
- DRUG Sevelamer carbonate
- DRUG Genz-644470
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853242
The ClinicalTrials.gov registry entry for NCT00853242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00853242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853242 about?
NCT00853242 is a clinical study titled "Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis". The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.
What is the current status of trial NCT00853242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 349 participants. The study started on 2009-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00853242?
The interventions under investigation include: Placebo (DRUG), Sevelamer carbonate (DRUG), Genz-644470 (DRUG).
Who is sponsoring clinical trial NCT00853242?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.